Polyethylene glycol 3350 and Lisinopril drug interactions - from FDA reports

Summary

Drug interactions are reported among people who take Polyethylene glycol 3350 and Lisinopril together. This study is created by eHealthMe based on reports of 19 people who take Polyethylene glycol 3350 and Lisinopril from FDA, and is updated regularly.



What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on polyethylene glycol 3350 and lisinopril (the active ingredients of Polyethylene glycol 3350 and Lisinopril, respectively), and Polyethylene glycol 3350 and Lisinopril (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

What is Polyethylene glycol 3350?

Polyethylene glycol 3350 has active ingredients of polyethylene glycol 3350. It is often used in constipation. (latest outcomes from Polyethylene glycol 3350 395 users)

What is Lisinopril?

Lisinopril has active ingredients of lisinopril. It is often used in high blood pressure. (latest outcomes from Lisinopril 228,281 users)

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.


On Feb, 24, 2019

19 people who take Polyethylene glycol 3350, Lisinopril are studied.


Number of reports submitted per year:

Polyethylene glycol 3350 and Lisinopril drug interactions.

Most common drug interactions over time *:

< 1 month:

n/a

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:
  1. Chest pain
  2. Dyspnoea (difficult or laboured respiration)
  3. Mitral valve disease (disease of mitral valve of heart)
  4. Neuropathy peripheral (surface nerve damage)
  5. Pancreatitis chronic (chronic inflammation of pancreas)
  6. Transaminases increased
  7. Asthenia (weakness)
  8. Dizziness
  9. Mitral valve prolapse (heart's mitral valve doesn't work well)
  10. Type 2 diabetes mellitus

Most common drug interactions by gender *:

female:
  1. Chest pain
  2. Back injury
  3. Cardiac disorder
  4. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  5. Hyperglycaemia (high blood sugar)
  6. Pancreatitis (inflammation of pancreas)
  7. Angina unstable (chest pain due to ischemia of the heart muscle- unstable)
  8. Arrhythmia (irregular heartbeat)
  9. Cardiomyopathy (weakening of the heart muscle)
  10. Mitral valve disease (disease of mitral valve of heart)
male:
  1. Dyspnoea (difficult or laboured respiration)
  2. Erythema (redness of the skin)
  3. Hypophagia (reduced food intake)
  4. Oedema peripheral (superficial swelling)
  5. Prostate cancer
  6. Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
  7. Small intestinal obstruction (blockage in small intestine)
  8. Weight increased
  9. Swollen tongue (swelling of tongue)
  10. Condition

Most common drug interactions by age *:

0-1:

n/a

2-9:
  1. Confusional state
  2. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  3. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
10-19:

n/a

20-29:

n/a

30-39:
  1. Arrhythmia (irregular heartbeat)
  2. Cardiomyopathy (weakening of the heart muscle)
  3. Chest pain
  4. Mitral valve disease (disease of mitral valve of heart)
  5. Neuropathy peripheral (surface nerve damage)
  6. Pancreatitis chronic (chronic inflammation of pancreas)
  7. Transaminases increased
  8. Back injury
  9. Cardiac disorder
  10. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
40-49:
  1. Angina unstable (chest pain due to ischemia of the heart muscle- unstable)
  2. Arrhythmia (irregular heartbeat)
  3. Back injury
  4. Cardiac disorder
  5. Cardiomyopathy (weakening of the heart muscle)
  6. Chest pain
  7. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  8. Hyperglycaemia (high blood sugar)
  9. Mitral valve disease (disease of mitral valve of heart)
  10. Neuropathy peripheral (surface nerve damage)
50-59:
  1. Alopecia (absence of hair from areas of the body)
  2. Anxiety
  3. Asthenia (weakness)
  4. Breast cancer
  5. Cellulitis (infection under the skin)
  6. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  7. Chemotherapy
  8. Chest pain
  9. Compression fracture (fracture due to pressure caused by injury)
  10. Decreased activity
60+:
  1. Dyspnoea (difficult or laboured respiration)
  2. Erythema (redness of the skin)
  3. Confusional state
  4. Dehydration (dryness resulting from the removal of water)
  5. Depressed level of consciousness
  6. Diarrhoea
  7. Dizziness
  8. Drug effect decreased
  9. Fluid retention (an abnormal accumulation of fluid in the blood)
  10. Gait disturbance

* Approximation only. Some reports may have incomplete information.


Do you take Polyethylene glycol 3350 and Lisinopril?

You are not alone:




Related publications that referenced our studies

Related studies

Browse interactions by gender and age

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+


Interactions between Polyethylene glycol 3350 and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Interactions between Lisinopril and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Browse all drug interactions of Polyethylene glycol 3350 and Lisinopril
a b c d e f g h i j k l m n o p q r s t u v w x y z

What would happen?

Predict new side effects and undetected conditions when you take Polyethylene glycol 3350 and Lisinopril (45,228 reports studied)



FDA reports used in this study


Recent updates

Recent general studies
Recent personal studies


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.